What would your predictions be for 7 years down the road and by the way please read the eye chart below out loud. How’s your vision? Today’s post is a chance to let one’s optimism and excitement about stem cells run a bit wild looking ahead not to next year, but 7 years ahead to […]
20/20 Stem Cell Predictions for the Year 2020 Read More »
IntelliCell BioSciences, Inc. of New York, a clinical stem cell establishment, has had a rough time of it lately. For example, a recent piece of bad news is that there is an impending foreclosure sale of the company’s assets. What exactly that means for the company more broadly remains unknown, but a few people tell me (take this
New FDA IntelliCell BioSciences, Audit Report: A Lot of Work to Do Read More »
IntelliCell BioSciences has had a terrible year. Well, there’s terrible and then there’s terrible! Things seem to be getting worse. For background, I detailed its troubles, ups, and downs here in a previous post. I was just working on a new draft post on the most recent, concerning FDA 483 report on the company, which I
IntelliCell Foreclosure Sale Read More »
In about a month my new book, Stem Cells: An Insider’s Guide, should be available as an e-book from the publisher and from Amazon. It’s available for pre-order now at Amazon here. The “real” book (i.e. the one made of paper) should be available in September. The book costs $29. Any writers out there interested in doing
Stem Cells An Insider’s Guide: More on My New Book Read More »
Every now and I then I try to take some time to think about the focus of this blog and the direction it is going. In the most recent case, I got the feeling that perhaps I have giving too discouraged or negative an impression on the blog lately….focusing too much on the challenges and
Why I am very optimistic about the future of the stem cell field Read More »
This is the fourth post in a series I’m doing on an FOIA release of letters between Texas stem cell clinic Celltex and the FDA. The first three posts, which include helpful background and discussion of other FOIA material from Celltex, can be found here, here, and here. Today’s post is focused on a newly
Celltex FDA FOIA Letter #3 Raises Key New Questions Read More »
A FOIA request that I made with the FDA in mid-December 2012 has at long last revealed letters from Celltex to the FDA that previously were not in the public domain. The reason for the FOIA and for these blog posts is to shed some light on important issues that particularly relate to patient safety. I
It was my pleasure recently to talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock
Interview with BioTime CEO Michael West Part 1: a little stem cell history Read More »
Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through
My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation Read More »
It’s difficult to make it as a biotech company, I would say stem cell biotechs in general may have an even rougher time, and one such company, Intellicell (Intellicell Biosciences, Inc), is showing a number of signs of distress in my opinion. An online financial tool predicts the probability of companies going bankrupt within the next
Stem cell company Intellicell facing new financial wrinkles Read More »